<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9976">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978405</url>
  </required_header>
  <id_info>
    <org_study_id>2013Wze088</org_study_id>
    <nct_id>NCT01978405</nct_id>
  </id_info>
  <brief_title>Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes</brief_title>
  <official_title>Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiang Guang-da</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-induced acute kidney injury (CIAKI) is a major complication with adverse outcomes
      after contrast media injection. Although the risk of developing CIAKI is low in patients
      with normal renal function, it is dramatically higher in patients with conditions such as
      diabetes mellitus (DM) or chronic kidney disease (CKD). More recently, our data showed that
      contrast agents can induce endothelial dysfunction partially via free radicals in diabetes.
      Therefore, strategies to prevent CIAKI and endothelial dysfunction in DM patients with CKD
      are urgently needed. Alpha-lipoic acid and its reduced form, dihydrolipoate, are potent
      antioxidants. We hypothesized that alpha lipoic acid can prevent the contrast-induced acute
      kidney injury and endothelial dysfunction in type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Contrast induced acte kidney injury</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The changes of endothelium-dependent arterial dilation before and after contrast administrated</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>The Changes of Plasma Creatinine</condition>
  <condition>The Changes of Plasma Free Radicals</condition>
  <condition>The Changes of Endothelium-dependent Arterial Dilation</condition>
  <arm_group>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo intervention group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only 0.9% sodium chloride 250 ml was given for this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha lipoic acid</intervention_name>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
    <arm_group_label>Placebo intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  nephropathy (stage 3 and 4)

        Exclusion Criteria:

          -  recive alpha lipoic acid

          -  type 1 diabetes

          -  nephropathy (stagte 1, 2 and 5)

          -  hypersensitivity to contrast media

          -  IV heart failure

          -  lactic acidosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Guangda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Guangda, MD</last_name>
    <phone>+8602768878410</phone>
    <email>Guangda64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Guangda, MD</last_name>
      <phone>+8602768878410</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>October 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Xiang Guang-da</investigator_full_name>
    <investigator_title>Director of Endocrinol Dept.</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Contrast medium</keyword>
  <keyword>Alpha lipoic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
